On the occasion of a symposium in Salzburg, an international team of clinicians and pharmacologists presented recent results in profile efficacy, safety and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will be the clinical outcome in patients with nosocomial pneumonia and other infections of the lower respiratory tract.
|Publisher:||Springer Berlin Heidelberg|
|Edition description:||Softcover reprint of the original 1st ed. 1994|
|Product dimensions:||6.10(w) x 9.25(h) x 0.01(d)|
Table of ContentsEffect of Quinolones Against Slowly Growing Bacteria.- The Postantibiotic Effect of Ciprofloxacin.- The Effects of Different Types of Antimicrobial Agents on Plasma Endotoxin Activity in Gram-Negative Bacterial Infection.- Dose-Finding Investigations of Intravenous Ciprofloxacin in a Pharmacodynamic Model.- The Relationship Between Ciprofloxacin Blood Concentrations, MIC Values, Bacterial Eradication, and Clinical Outcome in Patients with Nosocomial Pneumonia.- Efficacy and Safety of Ciprofloxacin in Various Intravenous Dosages.- Intravenous Ciprofloxacin Versus Imipenem/Cilastatin in the Treatment of Severe Pneumonia.- Conversion of Intravenous to Oral Ciprofloxacin: Observing the “Like-to-Like” Phenomenon.- Therapeutic Use of Quinolones in Oncology.- Ciprofloxacin in Neutropenic Host Infection.- Intravenous Ciprofloxacin for the Treatment of Lower Respiratory Tract Infections: Preliminary Results.- Integrated Safety Profile of Intravenous Ciprofloxacin.